Drug Profile
MK 7288
Alternative Names: MK-7288Latest Information Update: 13 Mar 2014
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Sleep disorder therapies
- Mechanism of Action Histamine H3 receptor inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sleep apnoea syndrome
Most Recent Events
- 01 May 2013 No development reported - Phase-I for Sleep apnoea syndrome in USA (PO)